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Introduction
Recognition of the distinctive challenges in providing care 
to adolescents and young adults (AYA) with cancer has grown 
over the past 30 years in numerous countries, stimulated in 
particular by groups of advocates who have in turn raised 
awareness and philanthropic funding while harnessing sup-
port from the cancer care community and agencies of fed-
eral governments. Several examples stand out.
CanTeen (http://www.canteen.org.au) was founded in 
Australia in 1985 and has grown into a national organization 
providing support to young people with cancer through more 
than 250 programs across the country. In recent years it has 
received substantial funding support from the federal gov-
ernment. This registered charity provides money for spe-
cialist hospital care, counselling and individual assistance as 
well as information and peer support programs.
The Teenage Cancer Trust (TCT) (http://teenagecancer-
trust.org/) began in the United Kingdom (UK) in 1990 and 
has built 25 facilities devoted to the care of those in this 
age group. It hosts biennial international workshops, most 
recently in July 2014, attracting participants from many 
countries. Prompted in part by this success, the National 
Institute for Health and Clinical Excellence in the UK has 
taken a position on “Improving Outcomes for Children and 
Young People with Cancer.”1
In the United States of America (USA), LiveStrong (then 
the Lance Armstrong Foundation that began in 1997) part-
nered with the National Cancer Institute (NCI) to form a 
Progress Review Group (PRG) in 2005 that focused uniquely 
not on a disease but on a population, those in the age range 
of 15-39 years.2 The PRG produced ive recommendations 
(table 1) on which work continues to be undertaken. 
LiveStrong formed the Young Adult Cancer Alliance, a con-
sortium of some 150 organizations that has gone on to inde-
pendence as a new entity called Critical Mass.
A National Task Force on AYA with cancer was born in Can-
ada in 2008 with support from C17, the network of all pedi-
atric cancer programs, and funding provided by the 
Canadian Partnership Against Cancer, an agency of the fed-
eral government. The Task Force has hosted biennial inter-
national workshops3,4 and produced six recommendations to 
advance the discipline of AYA oncology.5 Among its other ac-
complishments is the design of a national training program 
for oncologists as an Area of Focused Competence under the 
auspices of the Royal College of Physicians and Surgeons of 
Canada.
The clinical needs
A primary challenge is to deine the age group that spans 
the conventional pediatric and adult health care systems, 
but does not it well into either with respect to meeting the 
clinical needs of this population. Although the PRG in the 
USA adopted the age range of 15-39, it is clear that the 
needs of teenagers are substantially different from those 
who are approaching middle age. Moreover, in industrialized 
countries the incidence of cancer rises substantially across 
the PRG-deined age span, from 200 per million in the 15-19 
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recent improvement in this regard and the formation of an 
intergroup focused on AYA in the re-structured National Clin-
ical Trials Network in North America (igure 1) should be a 
further stimulus to remedying the deicit. This initiative will 
be able to address the need for AYA speciic clinical trials 
based on the evidence that, for some diseases (well exem-
pliied by acute lymphoblastic leukemia [ALL]) the outcome 
is better in young adults who are treated according to pedi-
atric rather than adult protocols.10
Disease distinctions
The spectrum of cancers affecting AYA is distinct from that 
affecting both younger and older people.11 Lymphomas, 
germ cell tumours, thyroid carcinomas and malignant mela-
noma account for approximately 60% of the total in the age 
group of 15-29 years (igure 2). An appreciation of this dis-
tinctiveness led to a proposed new classiication of cancer 
in AYA12 that has been adopted by the Surveillance, Epidemi-
ology and End Results Program of the NCI in the USA.
There is a growing understanding that the characteristics 
of individual diseases may also be different in AYA. This is true 
not only of ALL and solid tumours that are more common in 
childhood but also of some carcinomas, such as those of 
breast and colon, that are much more prevalent in older 
adults but do impact on AYA.13 These differences have impor-
tant prognostic implications. Moreover, improved knowledge 
of the differences aid therapeutic decision-making. For ex-
ample, more female AYA than older women with breast can-
cer have familial and “triple negative” disease (devoid of 
estrogen, progesterone and growth factor receptors). As fur-
ther evidence of the distinctive phenotypes and genotypes of 
cancers in AYA become available, this opens avenues for more 
targeted therapy and better clinical outcomes.
Table 1 Recommendations of the Progress Review Group 
on Adolescent and Young Adult Oncology (AYAO)
1. Identify the characteristics that distinguish the 
unique cancer burden in the AYAO patient
2. Provide education, training and communication to 
improve awareness, prevention, access and quality 
cancer care for AYAs
3. Create the tools to study the AYA cancer problem
4. Ensure excellence in service delivery across the 
cancer control continuum (from prevention to end 
of life)
5. Strengthen and promote advocacy and support of 
the AYA cancer patient
year age group to more than 1200 per million in the 35-39 
group. Accordingly a narrow age range has been used com-
monly, e.g. 15-25 for the evolution of specialized clinical 
services.6
Among the self-identiied needs of this population is psy-
cho-social support as these young people wrestle with such 
challenges as changes in body image, sexuality, relation-
ships with family and friends (including partners), return to 
education and employment, and inancial stressors. A spe-
ciic requirement to be met is in fertility preservation7 that, 
in the cancer population, has become an emerging disci-
pline (oncofertility)8 also.
A case has been made that accrual of AYA with cancer to 
therapeutic clinical trials has been especially deficient.9 
However, with the establishment of an AYA committee with-
in the Children’s Oncology Group in 2000 there has been 
Figure 1 Re-coniguration of the 
NCI Clinical Trials Network.
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Conclusions
It is hoped that this brief account of selected aspects of AYA 
oncology will serve, in some measure, to justify the emer-
gence of this new discipline. More importantly, it may in-
crease awareness of the special needs of AYA with cancer 
and attract a wide variety of health care professionals to 
form the multi-disciplinary teams that are essential to the 
provision of optimal care to this population. Likewise, there 
are important questions to be addressed in both tumour and 
host biology. The growing interest in AYA oncology has 
spawned a new journal (Journal of Adolescent and Young 
Adult Oncology) and the irst textbook devoted to the top-
ic.14 Meanwhile the role of advocacy cannot be over-esti-
mated. A strong, well-informed voice in support of AYA with 
cancer remains essential in harnessing the resources re-
quired for the development and sustainability of clinical 
programs focused on the special needs of this population 
and for a robust, relevant research agenda.
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Figure 2 Disease distribution among adolescents and young 
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